MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation expense
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Payment of deferred transaction ...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-22,371
-9,998
-11,894
-21,546
Depreciation expense
20
10
3
-
Stock-based compensation expense
1,224
333
638
965
Loss on extinguishment and on issuance of convertible promissory notes (including 169 and 34,692 for a related party)
-
0
0
-186
Change in fair value of derivative liabilities (including 1,165 and 2,039 for a related party)
-
0
0
1,229
Change in fair value of tranche liability (including 331 and 19,064 for a related party)
-
0
0
365
Non-cash interest expense (including 1,384 and 2,656 for a related party)
-
0
0
1,443
Non-cash operating lease expense
-85
-41
-12
-
Net amortization of premiums and accretion of discounts on marketable securities
334
316
83
-
Prepaid expenses and other current assets
1,042
-357
-2,041
588
Other non-current assets
796
-15
89
281
Accrued compensation
-
-
-
-1,073
Accounts payable
-232
874
-3,202
2,240
Accrued expenses and other current liabilities
867
1,725
151
268
Operating lease liabilities
-48
-98
17
-
Net cash used in operating activities
-22,627
-7,057
-11,333
-19,980
Purchases of marketable securities
70,181
0
34,523
-
Maturities of marketable securities
40,000
15,000
-
-
Purchase of property and equipment
-
17
183
-
Net cash used in investing activities
-30,181
14,983
-34,706
-
Proceeds from issuance of common stock in private placement
-
42,000
-
-
Proceeds from issuance of pre-funded warrants in private placement
-
8,000
-
-
Payment of issuance costs
-
1,669
-
-
Proceeds from the issuance of convertible promissory notes (including 3,402 and 19,041 from a related party), net of issuance costs
-
0
0
7,500
Cash acquired in connection with the merger
-
0
0
102,113
Payment of deferred transaction costs and issuance costs
2,156
591
0
2,346
Proceeds from the exercise of stock options
84
-
-
-
Net cash (used in) provided by financing activities
-2,072
47,740
0
107,267
Net (decrease) increase in cash and cash equivalents and restricted cash
-54,880
55,666
-46,039
87,287
Cash and cash equivalents and restricted cash, at beginning of the period
98,553
42,887
1,639
-
Cash and cash equivalents and restricted cash, at end of the period
43,673
98,553
42,887
-
Cash and cash equivalents
43,173
-
-
-
Restricted cash
500
-
-
-
Total cash, cash equivalents and restricted cash, at end of the period
43,673
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net (decrease)
increase in cash and cash...
-$54,880K
(-162.87%↓ Y/Y)
Maturities of marketable
securities
$40,000K
Stock-based compensation
expense
$1,224K
(26.84%↑ Y/Y)
Accrued expenses and
other current...
$867K
(223.51%↑ Y/Y)
Non-cash operating lease
expense
-$85K
Depreciation expense
$20K
Proceeds from the
exercise of stock options
$84K
Net cash used in
investing activities
-$30,181K
Net cash used in
operating activities
-$22,627K
(-13.25%↓ Y/Y)
Net cash (used in)
provided by financing...
-$2,072K
(-101.93%↓ Y/Y)
Canceled cashflow
$40,000K
Canceled cashflow
$2,196K
Canceled cashflow
$84K
Purchases of marketable
securities
$70,181K
Net loss
-$22,371K
(-3.83%↓ Y/Y)
Prepaid expenses and
other current assets
$1,042K
(77.21%↑ Y/Y)
Payment of deferred
transaction costs and...
$2,156K
(-8.10%↓ Y/Y)
Other non-current
assets
$796K
(183.27%↑ Y/Y)
Net amortization of
premiums and accretion of...
$334K
Accounts payable
-$232K
(-110.36%↓ Y/Y)
Operating lease
liabilities
-$48K
Buy us a coffee
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)